GO
Loading...

Bristol-Myers Squibb Co

More

  • Oct 10- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12- week course of treatment to rid patients of the liver-destroying viral infection. "Unfortunately, we believe that the price being demanded is still inappropriately high for a product targeting such a large group of...

  • Cramer: Activists are picking on the wrong chiefs Thursday, 9 Oct 2014 | 6:25 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention

  • Midday movers: Allergan, Deere, GoPro & More Tuesday, 7 Oct 2014 | 1:00 PM ET

    Some of Tuesday's midday movers:

  • NEW YORK, Oct 7- Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates. In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival...

  • Oct 7- Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country. Bristol-Myers is racing against Merck& Co and AbbVie to try and cut the treatment time by half and avoid side effects from older standard drugs interferon and ribavirin.

  • Oct 7- Bristol-Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C. Bristol-Myers said the combination treatment of daclatasvir and asunaprevir was approved in July for use in Japan. The company plans to submit additional data on daclatasvir from an ongoing study to the U.S. Food and Drug Administration.

  • LONDON, Oct 6- AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. AstraZeneca said on Monday it was the first time the cardiology organizations had recommended one drug of this type over another in the treatment of acute...

  • Oct 1- Portola Pharmaceuticals Inc said its drug met the main goal of reversing the effect of anti-coagulant drugs in a late-stage study. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the effect of Eliquis, an anti-clotting drug by Bristol-Myers Squibb Co and Pfizer Inc..

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • Cramer's Remix: Selloff strategies to survive drop Thursday, 25 Sep 2014 | 6:57 PM ET

    Upset by the spiral lower? Cramer feels your pain. And he’s developed strategies for surviving circumstances just like these.

  • Cramer’s Bristol-Myers theorem: What is it? Thursday, 25 Sep 2014 | 6:28 PM ET

    You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • Can anything slow Gilead down? Analysts say no Monday, 8 Sep 2014 | 3:12 PM ET
    Darryl Kato, research scientist for Gilead Sciences, works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster City, California, Feb. 8, 2012.

    Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Early movers: TIF, AAPL, T, AGN, PFE, TIVO & more Wednesday, 27 Aug 2014 | 8:13 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    Some of the names on the move ahead of the open.